RB
Therapeutic Areas
Kura Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tipifarnib | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations | Phase 2 |
| Novel Precision Medicines (unspecified) | Head and Neck Cancer, Lung Cancer, Acute Leukemias | Not Specified |
Leadership Team at Kura Oncology
TW
Troy Wilson, Ph.D., J.D.
President and Chief Executive Officer
TB
Teresa Bair, J.D.
Chief Legal Officer
FB
Francis Burrows, Ph.D.
Chief Scientific Officer
KF
Kathleen Ford
Chief Operating Officer
ML
Mollie Leoni, M.D.
Chief Medical Officer
BP
Brian Powl
Chief Commercial Officer
TD
Tom Doyle
Senior Vice President, Finance & Accounting
SV
Samir Vattompadam
Senior Vice President, Global Program Leadership
KM
Kevan M. Shokat, Ph.D.
UCSF Professor, Founding Team Member (Araxes Pharma)